ValuEngine upgraded shares of Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR) from a strong sell rating to a sell rating in a report issued on Saturday.

ALDR has been the subject of a number of other reports. Zacks Investment Research upgraded shares of Alder BioPharmaceuticals from a hold rating to a buy rating and set a $13.00 price target for the company in a research note on Tuesday, July 11th. Credit Suisse Group lowered shares of Alder BioPharmaceuticals from an outperform rating to a neutral rating and reduced their price target for the stock from $30.00 to $17.00 in a research note on Wednesday, June 28th. Mizuho reiterated a buy rating and issued a $32.00 price target on shares of Alder BioPharmaceuticals in a research note on Friday, September 15th. Wells Fargo & Company reiterated an outperform rating and issued a $51.00 price target on shares of Alder BioPharmaceuticals in a research note on Wednesday, June 28th. Finally, BMO Capital Markets reiterated an outperform rating and issued a $27.00 price target (down from $39.00) on shares of Alder BioPharmaceuticals in a research note on Wednesday, August 9th. Three research analysts have rated the stock with a sell rating, two have given a hold rating and ten have issued a buy rating to the company’s stock. Alder BioPharmaceuticals presently has a consensus rating of Hold and an average price target of $28.69.

Shares of Alder BioPharmaceuticals (ALDR) traded up 6.99% during mid-day trading on Friday, hitting $12.25. 1,756,242 shares of the company were exchanged. The company’s market capitalization is $829.48 million. Alder BioPharmaceuticals has a 52 week low of $8.60 and a 52 week high of $34.64. The company has a 50 day moving average of $9.64 and a 200 day moving average of $15.75.

Alder BioPharmaceuticals (NASDAQ:ALDR) last announced its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.48) EPS for the quarter, topping analysts’ consensus estimates of ($1.67) by $0.19. The company had revenue of $0.68 million during the quarter. During the same period in the previous year, the company earned ($0.79) EPS. The firm’s revenue for the quarter was up 518.2% on a year-over-year basis. Equities analysts anticipate that Alder BioPharmaceuticals will post ($5.60) earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “Alder BioPharmaceuticals, Inc. (ALDR) Upgraded by ValuEngine to “Sell”” was posted by Watch List News and is owned by of Watch List News. If you are viewing this article on another site, it was copied illegally and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at https://www.watchlistnews.com/alder-biopharmaceuticals-inc-aldr-upgraded-by-valuengine-to-sell/1601020.html.

In other news, Director Stephen M. Dow purchased 25,000 shares of the stock in a transaction on Tuesday, July 18th. The shares were acquired at an average price of $10.00 per share, with a total value of $250,000.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 10.60% of the company’s stock.

A number of large investors have recently modified their holdings of the business. Legal & General Group Plc lifted its holdings in Alder BioPharmaceuticals by 2.6% during the second quarter. Legal & General Group Plc now owns 15,496 shares of the biopharmaceutical company’s stock valued at $177,000 after purchasing an additional 400 shares in the last quarter. The Manufacturers Life Insurance Company lifted its holdings in Alder BioPharmaceuticals by 1.9% during the second quarter. The Manufacturers Life Insurance Company now owns 37,488 shares of the biopharmaceutical company’s stock valued at $430,000 after purchasing an additional 698 shares in the last quarter. Swiss National Bank lifted its holdings in Alder BioPharmaceuticals by 2.6% during the first quarter. Swiss National Bank now owns 66,342 shares of the biopharmaceutical company’s stock valued at $1,380,000 after purchasing an additional 1,700 shares in the last quarter. Voya Investment Management LLC lifted its holdings in Alder BioPharmaceuticals by 8.4% during the second quarter. Voya Investment Management LLC now owns 22,304 shares of the biopharmaceutical company’s stock valued at $255,000 after purchasing an additional 1,734 shares in the last quarter. Finally, American International Group Inc. lifted its holdings in Alder BioPharmaceuticals by 7.1% during the first quarter. American International Group Inc. now owns 28,849 shares of the biopharmaceutical company’s stock valued at $600,000 after purchasing an additional 1,910 shares in the last quarter. 76.16% of the stock is currently owned by institutional investors and hedge funds.

About Alder BioPharmaceuticals

Alder BioPharmaceuticals, Inc, is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder’s lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention.

Analyst Recommendations for Alder BioPharmaceuticals (NASDAQ:ALDR)

Receive News & Ratings for Alder BioPharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alder BioPharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.